FDB (First Databank, Inc.)’s Post

https://lnkd.in/gipsRP4t Stoked to publish my research paper on the safety of aztreonam versus ceftazidime in patients labelled with penicillin allergy! Moving forward, we may be able to use ceftazidime in such patient population, which appears to be cheaper and as well tolerated as aztreonam. Read the full article here on Clinical Therapeutics.

🚀 Exciting Development in Allergy Treatment! The FDA has officially approved neffy, the first needle-free epinephrine nasal spray for treating severe allergic reactions, including anaphylaxis. This breakthrough offers a safer, faster, and more accessible option for patients, eliminating the fear and pain associated with traditional needle injections. 🌟 This approval is a significant step forward in improving patient outcomes and making life-saving treatment more accessible. Kudos to all involved in bringing this innovation to market! 🙌 🔗 Read more about this approval and what it means for the future of allergy management: https://lnkd.in/e3ppUtPe #Pharmaceuticals #HealthcareInnovation #FDAApproval #AllergyTreatment #PatientSafety

We previously demonstrated that anti-IL4R dupilumab improves oscillometry defined small airway dysfunction versus anti-IL5R benralizumab (Chan et al, Allergy 2024). However, one of the key hallmarks of persistent asthma is airway hyperresponsiveness (AHR), also known as airway twitchiness, which can be measured using an inhaled sugar called mannitol. Our group has previously been shown that both benralizumab (Chan et al, J Allergy Clin Immunol. 2023 Mar;151(3):700-705.e10.) and dupilumab (Stewart et al, Am J Respir Crit Care Med 2024;209:A6701) attenuate mannitol AHR defined as the provocative dose required to drop forced expiratory volume in 1 second (FEV1) by 10% (PD10). In the current case matched indirect comparison of dupilumab versus benralizumab, we observe statistically significant improvements in mannitol AHR after 12 weeks of treatment with either biologic. However, between-treatment analysis detected significantly greater attenuation of mannitol AHR with dupilumab despite using a conservative statistical method where mannitol nonresponders were censored at 635mg (Sverrild et al Respir Res. 2021;22(1):287.) Moreover, the number of patients who achieved biological asthma remission, defined as clinical remission plus AHR remission, (Lipworth et al. J Allergy Clin Immunol Pract. 2024 Apr;12(4):904-907.) corresponded to 67% with anti-IL4R versus 25% with anti-IL5R p<0.05. Head to head studies powered on mannitol AHR as the primary outcome are now indicated to confirm these preliminary findings.

We previously demonstrated that anti-IL4R dupilumab improves oscillometry defined small airway dysfunction versus anti-IL5R benralizumab (Chan et al, Allergy 2024). However, one of the key hallmarks of persistent asthma is airway hyperresponsiveness (AHR), also known as airway twitchiness, which can be measured using an inhaled sugar called mannitol. Our group has previously been shown that both benralizumab (Chan et al, J Allergy Clin Immunol. 2023 Mar;151(3):700-705.e10.) and dupilumab (Stewart et al, Am J Respir Crit Care Med 2024;209:A6701) attenuate mannitol AHR defined as the provocative dose required to drop forced expiratory volume in 1 second (FEV1) by 10% (PD10). In the current case matched indirect comparison of dupilumab versus benralizumab, we observe statistically significant improvements in mannitol AHR after 12 weeks of treatment with either biologic. However, between-treatment analysis detected significantly greater attenuation of mannitol AHR with dupilumab despite using a conservative statistical method where mannitol nonresponders were censored at 635mg (Sverrild et al Respir Res. 2021;22(1):287.) Moreover, the number of patients who achieved biological asthma remission, defined as clinical remission plus AHR remission, (Lipworth et al. J Allergy Clin Immunol Pract. 2024 Apr;12(4):904-907.) corresponded to 67% with anti-IL4R versus 25% with anti-IL5R p<0.05. Head to head studies powered on mannitol AHR as the primary outcome are now indicated to confirm these preliminary findings.

Questioning the Benefit of Glucocorticoids in Acute Urticaria Recent findings suggest that the routine use of glucocorticoids in acute urticaria may not be as beneficial as previously thought. Two systematic reviews indicate that parenteral antihistamines are the most effective treatment option, while the role of glucocorticoids remains uncertain despite their frequent use in emergency care. This evidence reinforces the recommendation to use nonsedating second-generation antihistamines as the first line of treatment, reserving glucocorticoids for specific cases like significant angioedema or ongoing symptoms after several days of antihistamine therapy. -Evaluation of Pharmacological Treatments for Acute Urticaria: A Systematic Review and Meta-Analysis Sirinda Jamjanya et al. J Allergy Clin Immunol Pract. 2024 May. -Treatment of acute urticaria: A systematic review Fariza M S Badloe et al. J Eur Acad Dermatol Venereol. 2024. #ClinicalPharmacy #PharmacyPractice #AcuteUrticaria

🌱 Unlock Organic Growth in Your Allergy Practice! Read our most recent blog post and discover how to obtain significant growth by focusing on reactivating and retaining your immunotherapy patients, including those on SCIT (Subcutaneous Immunotherapy). Brevium’s advanced technology integrates with your practice management and vial tracking systems, streamlining patient recall, improving adherence, and optimizing long-term care plans. See how practices are enhancing patient outcomes and achieving sustainable growth by leveraging Brevium to keep SCIT patients on track with their treatment. 🔗 https://lnkd.in/gmETdCtb Ready to improve the patient experience and unlock your practice’s potential? Contact Brevium today! #AllergyPractice #PatientReactivation #PracticeGrowth #HealthcareInnovation #Immunotherapy #RevenueCycleManagement

FDA approves first nasal spray for treatment of anaphylaxis FDA has approved an epinephrine nasal spray (Neffy—ARS Pharmaceuticals) to treat anaphylaxis, making it the first product to deliver such treatment through a route other than injection. "Anaphylaxis is life-threatening and some people, particularly children, may delay or avoid treatment due to fear of injections," said Kelly Stone, MD, PhD, associate director of the Division of Pulmonology, Allergy and Critical Care at FDA's Center for Drug Evaluation and Research. "As a result, Neffy provides an important treatment option and addresses an unmet need." Regulatory approval hinged on four studies demonstrating that the epinephrine nasal spray was similarly safe and effective as currently available injection products. Neffy is indicated for children and adults who weight at least 30 kg, or about 66 pounds, with warnings for anyone with a history of nasal polyps or certain other nasal conditions and for users with certain coexisting conditions and allergic reactions associated with sulfite. For a typical user, common adverse effects may include throat irritation, nasal discomfort and congestion, tingling sensation, runny nose and sneezing, and gum pain, among others. https://lnkd.in/gNxamr2y

🌱 Wondering about the long-term benefits of allergen immunotherapy? 🤔 Kudos to our European colleagues Pål Johansen et al for recent research in JACI Global which sheds light on lasting effects! 📊💡 Studies show that for many allergy sufferers, immunotherapy can provide relief that lasts for years beyond treatment completion! Previous studies have shown continued benefit of intralymphatic immunotherapy (ILIT) for at least 3 years after treatment, but it's challenging to follow patients for long periods of time, especially when they feel good, so no one had studied longer than that. This new study, a follow-up to the first ILIT vs SCIT trial shows 76% of ILIT patients still symptom-free or reduced symptoms 19 YEARS AFTER TREATMENT! 🙌 Results were similar and not inferior to SCIT results. From reduced symptoms to decreased need for medication, it's a game-changer for managing allergies. Ready to say goodbye to sneezing and itching? 💪 Check out this enlightening article to learn more! #AllergyRelief #Immunotherapy #LongTermBenefits https://lnkd.in/gHHgUF3t

FDA approves first nasal spray for treatment of anaphylaxis FDA has approved an epinephrine nasal spray (Neffy—ARS Pharmaceuticals) to treat anaphylaxis, making it the first product to deliver such treatment through a route other than injection. "Anaphylaxis is life-threatening and some people, particularly children, may delay or avoid treatment due to fear of injections," said Kelly Stone, MD, PhD, associate director of the Division of Pulmonology, Allergy and Critical Care at FDA's Center for Drug Evaluation and Research. "As a result, Neffy provides an important treatment option and addresses an unmet need." Regulatory approval hinged on four studies demonstrating that the epinephrine nasal spray was similarly safe and effective as currently available injection products. Neffy is indicated for children and adults who weight at least 30 kg, or about 66 pounds, with warnings for anyone with a history of nasal polyps or certain other nasal conditions and for users with certain coexisting conditions and allergic reactions associated with sulfite. For a typical user, common adverse effects may include throat irritation, nasal discomfort and congestion, tingling sensation, runny nose and sneezing, and gum pain, among others. https://buff.ly/4fFWJB2

ICYMI: Cornea Update: Management of Ocular Allergy Itch With an Antihistamine-Releasing Contact Lens: Purpose: A contact lens (CL)-based drug delivery system for therapeutic delivery of the antihistamine ketotifen was tested in 2 parallel, conjunctival allergen challenge-based trials. Methods: Both trials employed the same multicenter, randomized, placebo-controlled protocol. Test lenses were etafilcon A with 0.019 mg ketotifen; control lenses were etafilcon A with no added drug. Subjects were randomized into 3 treatment groups. Group 1 received test lens in one eye and control lens in the contralateral eye; the eye chosen to receive test lens was randomly selected in a 1:1 ratio. Group 2 received test lenses bilaterally, and group 3 received control lenses bilaterally. Allergen challenges were conducted on 2 separate visits: following lens insertion, the subjects were challenged at 15 minutes (to test onset) and 12 hours (to test duration). The primary endpoint was ocular itching measured using a 0 to 4 scale with half-unit steps. Secondary endpoints included ciliary, conjunctival, and episcleral hyperemia. Results: The mean itching scores were lower for eyes wearing the test lens as compared to those that received control lenses, indicating that the test lens effectively reduced allergic responses. Mean differences in itching were statistically and clinically significant (mean score difference ≥ 1) at both onset and duration for both trials. Conclusions: This large-scale assessment (n = 244) is the first demonstration of efficacy for CL delivery of a therapeutic for ocular allergy. Results are comparable to direct topical drug delivery and suggest that the lens/ketotifen combination can provide a means of simultaneous vision correction and treatment for CL wearers with ocular allergies. http://dlvr.it/T8n8Vy #Cornea #MostPopularArticles #Ophthalmology